Cellectis SA (NASDAQ:CLLS) Q1 2023 Earnings Conference Call May 5, 2023 8:00 AM ET

Company Participants

Arthur Stril - Chief Business Officer

Andre Choulika - Co-Founder, CEO & Director

Mark Frattini - SVP, Clinical Sciences & Chief Medical Officer

Bing Wang - CFO

Conference Call Participants

Gena Wang - Barclays Bank

Yigal Nochomovitz - Citigroup

Anoumid Vaziri - Goldman Sachs Group

Dev Prasad - Jefferies

Hartaj Singh - Oppenheimer

Jack Allen - Robert W. Baird & Co.

Ingrid Gafanhao - Kempen

Silvan Tuerkcan - JMP Securities

Operator

Good morning, everyone, and welcome to Cellectis First quarter 2023 Earnings Call. [Operator Instructions].

Please be aware that today's conference call is being recorded. I'd now like to introduce the first speaker, Arthur Stril, Chief Business Officer. Please go ahead, sir.

Arthur Stril

Good morning, and welcome, everyone, to Cellectis' First Quarter 2023 Corporate Updates and Financial Results Conference Call.

Joining me on the call today with prepared remarks are Dr. Andre Choulika, our Chief Executive Officer; Dr. Bing Wang, our Chief Financial Officer; and Dr. Mark Frattini, our Chief Medical Officer.

Yesterday evening, Cellectis issued a press release reporting its financial results for the 3-month period ended March 31, 2023. The report and press release are available on our website at www.cellectis.com.

As a reminder, we will make statements regarding Cellectis' financial outlook in addition to its manufacturing, regulatory and product development standards and plans and product development of its license partners. These forward statements, which are based on our management's current expectations and assumptions and on information currently available to management, including information provided or otherwise publicly reported by our license partners are subject to risks and uncertainties that may cause actual results to differ from those forecasted. A description of these risks can be found in our most recent Form 20-F filed with the Securities and Exchange Commission, SEC, and the financial report, including the management reports for the year ended on December 31, 2022, and subsequent filings Cellectis makes with the SEC from time to time.

I would now like to turn the call over to Andre.

Andre Choulika

Thank you, Arthur. Good morning, and thank you, everyone, for joining us today. Cellectis made significant progress with it's pipeline this quarter. We took a notable step forward with the first patient being dosed in France with our in-house manufactured product candidate, UCART22 is evaluated in the BALLI-01 clinical study. This is an important advancement for the Cellectis' team who has worked tirelessly to expand the BALLI-01 clinical study to Europe.